-
公开(公告)号：US20230331861A1
公开(公告)日：2023-10-19
申请号：US18300064
申请日：2023-04-13
Applicant: Genentech, Inc.
Inventor： Junyan A. JI , Jacqueline Yvonne TYLER
Abstract: The disclosure provides pharmaceutical compositions comprising mosunetuzumab and methods of using the same.
-
102.发明公开公开(公告)号：US20230330106A1
公开(公告)日：2023-10-19
申请号：US18101377
申请日：2023-01-25
Applicant: Genentech, Inc.
Inventor： Kui Lin
IPC: A61K31/566 , A61K31/519 , A61K31/517
CPC classification number: A61K31/566 , A61K31/517 , A61K31/519 , A61K9/0019
Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.
-
公开(公告)号：US20230330023A1
公开(公告)日：2023-10-19
申请号：US18332324
申请日：2023-06-09
Applicant: GENENTECH, INC.
Inventor： Yuchen FAN , Chun-Wan YEN , Ke ZHANG
IPC: A61K9/127 , A61K31/713
CPC classification number: A61K9/1277 , A61K31/713 , B82Y5/00
Abstract: Provided herein are high throughput methods for optimizing and manufacturing various lipid nanoparticle (LNP) compositions and uses thereof. For example, in some embodiments, the present disclosure provides a high-throughput screening method for manufacturing a LNP composition comprising, obtaining at least two intermixable solutions comprising a payload and a plurality of molecules capable of self-assembly and mixing said at least two solutions under a set of controlled conditions, by which injection sequence, speed, volume, phase ratio and mixing duration are varied. In various embodiments, the present disclosure enables optimal encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability to be determined. The methods disclosed herein enable efficient optimization of manufacturing conditions for preparation of LNP-based therapeutics.
-
公开(公告)号：US11783366B2
公开(公告)日：2023-10-10
申请号：US17444691
申请日：2021-08-09
Applicant: Genentech, Inc.
Inventor： Gordon Bray , Iris Chan
IPC: A61K31/397 , A61K31/375 , A61P17/00 , A61P35/00 , A61P35/04 , G06Q30/0241 , A61K31/437 , C12Q1/6886 , A61K31/4523
CPC classification number: G06Q30/0241 , A61K31/437 , A61K31/4523 , C12Q1/6886 , C12Q2600/106 , A61K31/437 , A61K2300/00 , A61K31/4523 , A61K2300/00
Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.
-
105.发明公开公开(公告)号：US20230313189A1
公开(公告)日：2023-10-05
申请号：US18054116
申请日：2022-11-09
Applicant: Genentech, Inc.
Inventor： Alexander MUNK , Helene M. GYLLING , Jesse Eric HANSON , Lukasz J. KIELPINSKI
IPC: C12N15/113 , C12Q1/6883
CPC classification number: C12N15/113 , C12Q1/6883 , C12N2310/11 , C12N2310/3231 , C12N2310/315 , C12N2310/341 , C12N2310/3341
Abstract: The present invention relates to complement component 4 (C4) inhibitors for use in treatment of a neurological disease. The invention in particular relates to the use of C4 inhibitors for down-regulation of C4 expression. The invention also relates to nucleic acid molecules, which are complementary to C4A and/or C4B and capable of reducing the level of an C4A and/or C4B mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a neurological disease.
-
Patent Agency Ranking
公开(公告)号：US20230307135A1
公开(公告)日：2023-09-28
申请号：US18328278
申请日：2023-06-02
Applicant: Genentech, Inc. , Hoffmann La-Roche Inc.
Inventor： Fethallah BENMANSOUR , Daniela Ferrara CAVALCANTI
CPC classification number: G16H50/20 , G06T7/0012 , A61B3/12 , G06T2207/20084 , G06T2207/30041
Abstract: Methods and systems for evaluating diabetic retinopathy (DR) severity are provided herein. Color fundus imaging data is received for an eye being evaluated for DR. A metric is generated using the color fundus imaging data, the metric indicating a probability that a score for the DR severity in the eye falls within a selected range.
-
公开(公告)号：US11767370B2
公开(公告)日：2023-09-26
申请号：US17978913
申请日：2022-11-01
Applicant: Genentech, Inc. , Novartis AG
Inventor： Charles M. Winter
CPC classification number: C07K16/4291 , A61K39/39591 , B01D61/146 , B01D61/16 , C07K1/34 , C07K16/065 , B01D2311/04 , B01D2311/16 , C07K2317/21 , B01D2311/04 , B01D2311/10 , B01D2311/246
Abstract: This present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process of preparing highly concentrated antibody compositions. and highly concentrated antibody products.
-
108.发明授权公开(公告)号：US11767362B1
公开(公告)日：2023-09-26
申请号：US16084346
申请日：2017-03-14
Applicant: Chugai Seiyaku Kabushiki Kaisha , Genentech, Inc.
Inventor： Mika Endo , Atsuhiko Kato , Toshihiko Ohtomo , Kenji Adachi , Yasuko Kinoshita , Yoshinori Narita
CPC classification number: C07K16/2827 , A61P35/00 , C07K16/303 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/76
Abstract: The invention provides compositions and methods for treating cancers. The methods comprising administering a PD-1 axis binding antagonist and an anti-GPC3 antibody. The compositions comprising a pharmaceutical composition for treating cancer which comprises a PD-1 axis binding antagonist and an anti-GPC3 antibody. Also disclosed are a pharmaceutical composition to be used in combination with a PD-1 axis binding antagonist for treating cancer which comprises an anti-GPC3 antibody as the active ingredient; and a pharmaceutical composition to be used in combination with an anti-GPC3 antibody for treating cancer which comprises as the active ingredient a PD-1 axis binding antagonist.
-
公开(公告)号：US20230296620A1
公开(公告)日：2023-09-21
申请号：US17965406
申请日：2022-10-13
Applicant: Genentech, Inc.
Inventor： Keyang Xu , Jintang He , Surinder Kaur
CPC classification number: G01N33/6848 , G01N30/7233 , G01N30/20 , G01N30/32 , G01N30/88 , G01N30/463 , B01D15/325 , B01D15/1878 , G01N2333/976 , G01N2030/027
Abstract: The present application relates to systems and methods for assaying presence of large molecule analytes, such as proteins, e.g., antibodies, antigens, receptors, and the like, using a targeted two-dimensional liquid chromatography, tandem mass spectrometry (2D-LC-MS/MS) system, optionally combined with affinity capture. In some aspects, the system is partially or fully automated. In some aspects, the system may allow detection of protein biomarkers (e.g., antibodies or antigens) from clinical or nonclinical biological tissue or fluid samples in the pg/mL to ng/mL range.
-
公开(公告)号：US20230279090A1
公开(公告)日：2023-09-07
申请号：US18301187
申请日：2023-04-14
Applicant: Genentech, Inc. , HOFFMANN-LA ROCHE INC.
Inventor： Stefan Dengl , Rami Hannoush , Simon Theodor Hansen , Peter Michael Huelsmann , Robert Franklin Kelley , Hubert Kettenberger , Shrenik Chetan Mehta , Devin Brent Tesar
IPC: C07K16/22 , C07K14/705 , A61P27/02
CPC classification number: C07K16/22 , A61P27/02 , C07K14/70578 , C07K14/70585
Abstract: A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican.
-
-
-
-
-
-
-
-
-
Search Results
5303
records
(took 0.043 seconds)
